Ben Sasse discusses politics, AI, and experimental cancer treatment in televised interviews
Updated
Updated · CBS New York · Apr 27
Ben Sasse discusses politics, AI, and experimental cancer treatment in televised interviews
2 articles · Updated · CBS New York · Apr 27
Diagnosed with stage-four pancreatic cancer in late 2025, Sasse credits the experimental drug daraxonrasib for shrinking his tumors by 76% and extending his life beyond initial expectations.
He urges broader access to experimental treatments, critiques Congress for neglecting major issues like artificial intelligence, and calls for institutional reforms to address future societal disruptions.
Sasse reflects on mortality, family, and the need for deeper national deliberation, emphasizing gratitude and wisdom as he faces limited time due to his illness.
Does the 'Right to Try' law offer real hope or dangerous false promises?
A once 'undruggable' cancer target has been hit. What's the next medical frontier?
How can patients access breakthrough drugs before full FDA approval?
As AI reshapes our economy, what is the first step government must take?
If AI makes goods cheap but jobs scarce, how will society redefine work?
Experimental Drug Daraxonrasib Doubles Survival in Pancreatic Cancer: Ben Sasse’s Journey and Societal Reflections
Overview
Ben Sasse is battling Stage 4 pancreatic cancer and began treatment with the experimental drug daraxonrasib in December 2025, which has reduced his tumor volume by 76%. While the drug shows promising results and is nearing FDA approval, it causes severe skin side effects and requires careful pain management. This diagnosis has deeply changed Sasse’s outlook, strengthening his focus on faith, family, and political reform. He also warns about AI’s risks to society and advocates rebuilding strong, intergenerational communities. Using his public platform, Sasse raises awareness about pancreatic cancer and broader societal challenges, turning his personal struggle into a call for hope and meaningful change.